These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12497850)

  • 1. [Prevention of thromboembolism in non-valvular atrial fibrillation].
    Coccheri S; Cosmi B
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 2):927-9. PubMed ID: 12497850
    [No Abstract]   [Full Text] [Related]  

  • 2. [Thromboembolic complications in the course of non-valvular atrial fibrillation].
    Mas JL
    Rev Prat; 1995 Apr; 45(8):935-41. PubMed ID: 7761775
    [No Abstract]   [Full Text] [Related]  

  • 3. [The assessment of the thromboembolic risk and the role of antithrombotic prophylaxis in nonrheumatic atrial fibrillation].
    Fera MS; Giovannini E
    G Ital Cardiol; 1999 Feb; 29(2):193-213. PubMed ID: 10088078
    [No Abstract]   [Full Text] [Related]  

  • 4. "Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents.
    Francescone S; Halperin JL
    J Am Coll Cardiol; 2008 Feb; 51(8):826-7. PubMed ID: 18294567
    [No Abstract]   [Full Text] [Related]  

  • 5. [Thromboembolism risks in atrial fibrillation].
    Babuty D; Gorin L; Zannad N; Fauchier L
    Ann Cardiol Angeiol (Paris); 2009 Dec; 58 Suppl 1():S11-3. PubMed ID: 20103170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comment on the article by Vázquez and Márquez-Garcia. High-risk vs. low-risk for thrombo-embolic events: who are in the intermediate-risk group? What should be done then?
    Benchimol-Barbosa PR; Barbosa-Filho J
    Int J Cardiol; 2008 Mar; 124(3):358-9; author reply 360-1. PubMed ID: 17400310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is 'valvular' atrial fibrillation? A reappraisal.
    De Caterina R; Camm AJ
    Eur Heart J; 2014 Dec; 35(47):3328-35. PubMed ID: 25265975
    [No Abstract]   [Full Text] [Related]  

  • 8. [Why is it that "only" women with chronic non-valvular atrial fibrillation older than 75 years of age are at higher thromboembolic risk?].
    Lovreglio V
    Ital Heart J Suppl; 2000 Aug; 1(8):1078-9. PubMed ID: 10993024
    [No Abstract]   [Full Text] [Related]  

  • 9. [Risks in atrial fibrillation and simultaneous renal failure].
    Habich S
    Dtsch Med Wochenschr; 2012 Sep; 137(38):1840. PubMed ID: 23133847
    [No Abstract]   [Full Text] [Related]  

  • 10. Atrial fibrillation: food for thought in 2013.
    Alpert JS
    Am J Med; 2013 Nov; 126(11):937-8. PubMed ID: 24157284
    [No Abstract]   [Full Text] [Related]  

  • 11. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
    Själander A; Wallentin L; Rosenqvist M; Svensson P
    Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
    [No Abstract]   [Full Text] [Related]  

  • 12. Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation.
    Blustin JM; McBane RD; Ketha SS; Wysokinski WE
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1129-32. PubMed ID: 25244622
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China.
    Hu D; Sun Y
    J Am Coll Cardiol; 2008 Sep; 52(10):865-8. PubMed ID: 18755352
    [No Abstract]   [Full Text] [Related]  

  • 14. Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?
    Watson T; Lip GY
    Int J Clin Pract; 2006 Mar; 60(3):252-5. PubMed ID: 16494636
    [No Abstract]   [Full Text] [Related]  

  • 15. Evidence-based emergency medicine. Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
    Diner BM
    Ann Emerg Med; 2003 Jan; 41(1):141-3. PubMed ID: 12514695
    [No Abstract]   [Full Text] [Related]  

  • 16. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial appendage occlusion for prevention of thromboembolic events in patients with non-valvular atrial fibrillation: closing the door to hell.
    Klug D
    Arch Cardiovasc Dis; 2012 Dec; 105(12):619-22. PubMed ID: 23199616
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial fibrillation: steering a management course between thromboembolism and proarrhythmic risk.
    Campbell RW
    Eur Heart J; 1995 Aug; 16 Suppl G():28-31. PubMed ID: 8595797
    [No Abstract]   [Full Text] [Related]  

  • 20. [Atrial fibrillation. Risk of thromboembolic complications and their prevention].
    Petersen P; Kastrup J; Bartram R; Godtfredsen J
    Ugeskr Laeger; 1984 Mar; 146(11):789-92. PubMed ID: 6719572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.